Alinidine (BioDeep_00000175853)
human metabolite blood metabolite
代谢物信息卡片
N-(2,6-dichlorophenyl)-N-(prop-2-en-1-yl)-4,5-dihydro-1H-imidazol-2-amine
化学式: C12H13Cl2N3 (269.0486478)
中文名称: 烯丙尼定
谱图信息:
最多检出来源 Homo sapiens(blood) 97.83%
分子结构信息
SMILES: C=CCN(C1=C(C=CC=C1Cl)Cl)C2=NCCN2
InChI: InChI=1S/C12H13Cl2N3/c1-2-8-17(12-15-6-7-16-12)11-9(13)4-3-5-10(11)14/h2-5H,1,6-8H2,(H,15,16)
描述信息
C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist
D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents
同义名列表
数据库引用编号
7 个数据库交叉引用编号
- PubChem: 36354
- HMDB: HMDB0248138
- ChEMBL: CHEMBL278581
- Wikipedia: Alinidine
- KNApSAcK: C00026351
- chemspider: 33429
- CAS: 33178-86-8
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Tobie D Lee, Olivia W Lee, Kyle R Brimacombe, Lu Chen, Rajarshi Guha, Sabrina Lusvarghi, Bethilehem G Tebase, Carleen Klumpp-Thomas, Robert W Robey, Suresh V Ambudkar, Min Shen, Michael M Gottesman, Matthew D Hall. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Molecular pharmacology.
2019 11; 96(5):629-640. doi:
10.1124/mol.119.115964. [PMID: 31515284] - I Rustenbeck, M Winkler, A Jörns. Desensitization of insulin secretory response to imidazolines, tolbutamide, and quinine. I. Secretory and morphological studies.
Biochemical pharmacology.
2001 Dec; 62(12):1685-94. doi:
10.1016/s0006-2952(01)00792-4. [PMID: 11755122] - I Rustenbeck, C Dickel, T Grimmsmanns. Desensitization of insulin secretory response to imidazolines, tolbutamide, and quinine. II. Electrophysiological and fluorimetric studies.
Biochemical pharmacology.
2001 Dec; 62(12):1695-703. doi:
10.1016/s0006-2952(01)00793-6. [PMID: 11755123] - I Rustenbeck, L Leupolt, R Kowalewski, A Hasselblatt. Heterogeneous characteristics of imidazoline-induced insulin secretion.
Naunyn-Schmiedeberg's archives of pharmacology.
1999 Mar; 359(3):235-42. doi:
10.1007/pl00005347. [PMID: 10208311] - M Boucher, C Chassaing, E Chapuy. Cardiac electrophysiologic effects of alinidine, a specific bradycardic agent, in the conscious dog: plasma concentration-response relations.
Journal of cardiovascular pharmacology.
1995 Feb; 25(2):229-33. doi:
10.1097/00005344-199502000-00007. [PMID: 7752648] - J C Jonas, T D Plant, J C Henquin. Imidazoline antagonists of alpha 2-adrenoceptors increase insulin release in vitro by inhibiting ATP-sensitive K+ channels in pancreatic beta-cells.
British journal of pharmacology.
1992 Sep; 107(1):8-14. doi:
10.1111/j.1476-5381.1992.tb14456.x. [PMID: 1358388] - H Ditter, K D Müller, H Bahavar, M Schlepper. [Alinidine in multi-vessel coronary disease: reduction of stress-induced ischemic reaction].
Zeitschrift fur Kardiologie.
1991 Feb; 80(2):167-70. doi:
NULL. [PMID: 2058248] - M Boucher, E Chapuy, M A Lefebvre, A Mignot, P Duchêne-Marullaz. Mechanisms of chronotropic cardiac effects of alinidine and plasma concentration-response relationships in the conscious dog with chronic atrioventricular block.
Naunyn-Schmiedeberg's archives of pharmacology.
1989 Jun; 339(6):630-7. doi:
10.1007/bf00168655. [PMID: 2570365] - A E Arnold, A L Soward, S H Meij, G A van Es, P W Serruys. Assessment of the bradycardic and inotropic properties of ST 567 using a new scheme of administration.
European heart journal.
1987 Dec; 8 Suppl L(?):99-104. doi:
10.1093/eurheartj/8.suppl_l.99. [PMID: 3451889] - K Skarvan. Value of a specific bradycardic agent in cardiac surgery compared to placebo.
European heart journal.
1987 Dec; 8 Suppl L(?):123-9. doi:
10.1093/eurheartj/8.suppl_l.123. [PMID: 3451878] - W D Bechtel, I Richter. Blood level, distribution, metabolite pattern and excretion of [14C]alinidine in mice and rats.
European journal of drug metabolism and pharmacokinetics.
1986 Jul; 11(3):175-86. doi:
10.1007/bf03189845. [PMID: 3816873] - D P Nicholls, J McNeill, P C O'Connor, D W Harron, W J Leahey, R G Shanks. Effect of indoramin, labetalol and alinidine on sympathetic function in normal man.
British journal of clinical pharmacology.
1984 Aug; 18(2):215-21. doi:
10.1111/j.1365-2125.1984.tb02455.x. [PMID: 6386022] - D W Harron, D Arndts, M Finch, R G Shanks. An assessment of the contribution of clonidine metabolised from alinidine to the cardiovascular effects of alinidine.
British journal of clinical pharmacology.
1983 Oct; 16(4):451-5. doi:
10.1111/j.1365-2125.1983.tb02196.x. [PMID: 6626441] - B Stanek, W Reiterer, P Placheta, G Raberger. Acute effects of alinidine on heart rate and blood pressure in healthy subjects and patients with hyperkinetic heart syndrome.
European journal of clinical pharmacology.
1983; 24(1):31-4. doi:
10.1007/bf00613923. [PMID: 6832198] - D W Harron, D Arndts, R G Shanks. Alinidine pharmacokinetics following acute and chronic dosing.
British journal of clinical pharmacology.
1982 Jun; 13(6):821-7. doi:
10.1111/j.1365-2125.1982.tb01873.x. [PMID: 7093113] - U W Wiegand, W Kasper, T Meinertz, U Stützle, E Jähnchen. Pharmacokinetic and pharmacodynamic properties of alinidine in man.
Journal of cardiovascular pharmacology.
1982 Jan; 4(1):59-62. doi:
10.1097/00005344-198201000-00010. [PMID: 6176801] - D Arndts, H Stähle. Development and quality control of a highly sensitive radioimmunoassay for alinidine.
Journal of pharmacological methods.
1981 Sep; 6(2):109-20. doi:
10.1016/0160-5402(81)90033-4. [PMID: 7289628] - P D Verdouw, J M Hartog, A M Ruggeman. Systemic and regional myocardial responses to AR-L 115 BS, a positive inotropic imidazo-pyridine, in the absence or in the presence of the bradycardiac action of alinidine.
Basic research in cardiology.
1981 May; 76(3):328-43. doi:
10.1007/bf01907776. [PMID: 7271723] - U W Wiegand, T Meinertz, W Kasper, E Jähnchen. Determination of alinidine in human plasma by high-performance liquid chromatography.
Journal of chromatography.
1981 Apr; 223(1):238-42. doi:
10.1016/s0378-4347(00)80093-6. [PMID: 7251771] - D Arndts, G Leb, H J Förster. Pharmacokinetics and metabolism of 14C-labelled alinidine in man and dogs.
European journal of drug metabolism and pharmacokinetics.
1981; 6(3):225-36. doi:
10.1007/bf03189492. [PMID: 7308242] - D Arndts, H Warnkross, K L Rominger, H Justus. Proof of the linearity of the pharmacokinetics of alinidine in man.
European journal of clinical pharmacology.
1981; 21(3):201-7. doi:
10.1007/bf00627921. [PMID: 7318879] - P D Verdouw, P R Saxena, H C Schamhardt, T M van der Hoek, A M Rutteman. The effects of alinidine, an N-allyl derivative of clonidine, on regional myocardial perfusion and performance in the pig with or without atrial pacing.
European journal of pharmacology.
1980 Jun; 64(4):209-20. doi:
10.1016/0014-2999(80)90228-9. [PMID: 7389819]